Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy

In this systematic review, originally published in the journal Future Oncology, researchers describe the quality of the reporting of adverse events in publications of pivotal clinical trials testing new drugs in solid tumors. The detailed knowledge of the risks associated with the administration of anti-cancer treatments is crucial for multiple stakeholders, including regulatory authorities, clinical researchers, physicians and — of course — patients. Approximately 20 years ago, the Outcomes Working Group of the American Society of Clinical Oncology’s Health Research Committee defined toxicity as a vitally important outcome, to be used for technology assessment and development of cancer treatment guidelines....